Delivering new discoveries advancing regenerative medicine...

...Through tireless effort and dedication of pioneers in regenerative medicine...

...Expanding applications to human and animal degenerative medical conditions

Regenerative medicine has been called the “next evolution of medical treatments,” by the U.S. Department of Health and Human Services. “With its potential to heal, this new field of science is expected to revolutionize health care.”
Tithon Biotech is a commercially driven biotechnology company engaged, in the development of biomedical solutions addressing various degenerative medical conditions affecting both humans and animals. Our technology result from years of both private and university research and development by pioneers in the field of biotechnology, in collaboration with medical practitioners within various fields of medicine throughout the world.

Our Vision

Our vision is to develop and to provide medical solutions, based upon our advanced new discoveries, to aid both humans and animals around the world who are suffering from various types of degenerative medical conditions.

Our Mission

Through the efforts and dedication of our science team, and those collaborators within the medical community who share our vision and mission, we pursue our vision tirelessly, seeking new means to relieve suffering from degenerative medical conditions.

Our Core Technology


We have recently identified never before naturally available pluripotent stem cells recoverable from peripheral blood with universal applications in human and animal therapeutics and tissue engineering and ideal for human and animal cell banking

Introducing Peripheral Blood Derived Pluripotent Stem Cell Technology (“nPSC Technology “)

Non-Immunogenic & Non-tumerogenic

Demonstrated to be non-immunogenic and non-tumerogenic

Recovered From Peripheral Blood

Easily harvested from peripheral or cord blood in acceptable quantities for a a number of applications including banking,  therapeutic and tissue enginerring uses

No Expansion Required

No Expansion Required for cell banking or a number of therapeutic applications

A "Blood Component"

Proprietary recovery proceedure falls within the definition of a “blood component” under existing FDA definitions

Demonstrated Pluripotent

Tested and proven existence and characterization using all known markers for pluripotency